BGI Genomics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Lijian Zhao

İcra Kurulu Başkanı

CN¥1.4m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.4yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Lijian Zhao (48 yo)

3.4yrs

Görev süresi

CN¥1,361,400

Tazminat

Mr. Lijian Zhao serves as Non Independent Director of BGI Genomics Co, Ltd from June 18, 2024. He serves as a Director of BGI Genomics Co., Ltd., since June 17, 2021 and serves its General Manager.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lijian Zhao	Non Independent Director & GM	3.4yrs	CN¥1.36m	0.045% CN¥ 7.7m
Yujue Wang	CFO, Deputy GM & Non Independent Director	less than a year	CN¥917.50k	0.0074% CN¥ 1.3m
Ning Li	Non Independent Director & Deputy GM	1.2yrs	CN¥1.07m	0.032% CN¥ 5.5m
Zhu Shida	Non Independent Director & Deputy General Manager	less than a year	CN¥1.10m	Veri yok
Leroy Hood	Member of Scientific Advisory Board	7.7yrs	Veri yok	Veri yok
Jian Wang	Non Independent Director & Chairman	9.4yrs	Veri yok	0.67% CN¥ 113.7m
Hongtao Wang	Director	8.7yrs	Veri yok	Veri yok
Ya Cao	Independent Director	3.4yrs	CN¥252.00k	Veri yok
Lan Du	Independent Director	3.4yrs	CN¥252.00k	Veri yok
Siqi Liu	Chairman of the Supervisory Board	3.4yrs	Veri yok	Veri yok
Lisheng Yu	Independent Director	1.3yrs	CN¥108.80k	Veri yok
Guocheng Zhang	Non Independent Director	less than a year	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300676 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

BGI Genomics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

BGI Genomics Co., Ltd. Announces Board Appointments

BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023)

BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023)

High number of new directors

BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

BGI Genomics Co., Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 4 July 2024

BGI Genomics Co., Ltd. Announces Board Appointments

Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023

Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024

BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022)

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022)

BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023

Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023

First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022)

Investor sentiment improves as stock rises 30%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021)

BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022

BGI Genomics Co., Ltd. Approves Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥1.29 in 1Q 2021)

Less than half of directors are independent

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020)

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Investor sentiment improved over the past week

BGI Genomics Co., Ltd. (SZSE:300676) completed the acquisition of remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd.

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

BGI Genomics Co., Ltd. Approves Cash Dividend for 2020

BGI Genomics Co., Ltd. (SZSE:300676) agreed to acquire the remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd. for CNY 2.37 million.

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2020

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020)

New 90-day low: CN¥125

Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019)

Revenue misses expectations

Investor sentiment deteriorated over the past week

New 90-day high: CN¥166

Investor sentiment improved over the past week

New 90-day low: CN¥127

New 90-day low: CN¥132

Third quarter earnings released

New 90-day low: CN¥133

First half earnings released

BGI Genomics Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

BGI Genomics Co., Ltd. announced that it expects to receive CNY 2.0119372 billion in funding

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş